Simcere Zaiming’s Pan-RAS Inhibitor SIM0532 Doses First Patient in Clinical Trial
Simcere Zaiming’s LRRC15-Targeting ADC SIM0613 Receives IND Approval in China
FDA Granted Fast Track Designation for SIM0505 (CDH6 ADC) for the Treatment of Ovarian Cancer
Rademikibart Phase III Data Presented as Late-Breaking Oral at AAD Annual Meeting
Phase I/II NMBIC Data of SIM0237 Releases as Oral presentation at the 2026 EAU26
Deuremidevir Hydrobromide Dry Suspension Doses First Patient in Phase 3 Clinical Trial for RSV Infection
Novel Anti-Stroke Candidate SIM0811 Doses First Participant in Phase I Clinical Trial
Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease
Simcere Zaiming's a Bispecific ADC SIM0610 Doses First Patient in a Phase I Clinical Trial
Simcere Announces Positive Phase III Topline Data of Zemprocitinib (LNK01001) in Rheumatoid Arthritis
Telephone: 025-85566666 Fax：025-85262330
Address: 699-18 Xuanwu Avenue Nanjing China
Zipcode：210042
Fax：025-85471729
Su ICP Bei No. 10205883 Su Gong Wang An Bei No. 32010202010345 Su ICP Bei No. 08104641-3 | (Su)–Non-business–2018-0092 (Internet Drug Information Service Qualification Certificate) ? Copyright 2016 Jiangsu Simcere Pharmaceutical Co., Ltd. 版权所有 All Rights Reserved.